In this study, we evaluated low dose intravesical bacillus Calmette-Guerin (BCG) therapy following transurethral resection (TUR) in 80 patients with superficial bladder cancer. The patients were divided into two groups. Of the Connaught BCG strain 81 mg was given to 40 patients in Group 1 and 54 mg to the remainder of 40 patients in Group 2. BCG was introduced once a week for 6 weeks. Tumour recurrence was seen in 6 patients in Group 1 and in 10 patients in Group 2. Recurrence rates per month were 0.71 and 1.49, respectively. There was no significant difference in complication rates. These data suggest that while the standard dose (81 mg) intravesical therapy of BCG is more effective than the low dose, there was no significant difference in side effects between the two groups.
Three patients with leiomyosarcoma of the urinary bladder are presented. One case showed urothelial carcinoma in situ also. The mode of presentation and operative findings were similar in two female patients, whereas the lesion seemed to be more aggressive in a male patient.
In the Inter~iational Urology and Neplirology publication (1998) 30 ( I ) , on page 41 in the second and fourth paragraphs there was a reference to "...Intravesical BCG (IMMUNOCYT) ...". and "The Connaught BCG strain (IMMUNOCYT) ...". 'flie proper brarid name for the Connaught BCG bladder cancer therapeutic is IMMUCYST', and not IMMUNOCYT as stated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.